(Q38386705)

2 September 2017

1 reference

title

Emerging formats for next-generation antibody drug conjugates (English)

1 reference

2 September 2017

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25797303%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Mahendra P Deonarain

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25797303%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Gokhan Yahioglu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25797303%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Ioanna Stamati

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25797303%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

23 March 2015

1 reference

Expert Opinion on Drug Discovery

2 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25797303%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25797303%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25797303%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

463-481

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25797303%20AND%20SRC:MED&resulttype=core&format=json

Antibody-drug conjugates.

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Antibody-drug conjugates: present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Antibody-drug conjugates: an emerging concept in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Antibody-drug conjugates for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Risks and untoward toxicities of antibody-based immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Antibody-drug conjugates: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Antibody discovery: sourcing of monoclonal antibody variable domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Investigation into temperature-induced aggregation of an antibody drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Analytical methods for physicochemical characterization of antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Site-specific antibody-drug conjugation through glycoengineering.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Site-specific antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Methods for site-specific drug conjugation to antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Antibody conjugation via one and two C-terminal selenocysteines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Chemically programmed antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Unnatural amino acids in novel antibody conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

A general approach to site-specific antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Genetic incorporation of multiple unnatural amino acids into proteins in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

A Pictet-Spengler ligation for protein chemical modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Facile and stabile linkages through tyrosine: bioconjugation strategies with the tyrosine-click reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Probody therapeutics for targeting antibodies to diseased tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Bispecific digoxigenin-binding antibodies for targeted payload delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Engineered antibody fragments and the rise of single domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Microbials for the production of monoclonal antibodies and antibody fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-Taxol conjugate on A431 epidermoid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Bridging disulfides for stable and defined antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of antitumor agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Anti-CD30 diabody-drug conjugates with potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Armed antibodies for cancer treatment: a promising tool in a changing era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

A chemically defined trifunctional antibody-cytokine-drug conjugate with potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Engineered Fc based antibody domains and fragments as novel scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Improving the serum stability of site-specific antibody conjugates with sulfone linkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

A bioorthogonal (68)Ga-labelling strategy for rapid in vivo imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Orthogonal Assembly of a Designed Ankyrin Repeat Protein–Cytotoxin Conjugate with a Clickable Serum Albumin Module for Half-Life Extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

Cysteine-Selective Reactions for Antibody Conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1025049

10.1517/17460441.2015.1025049

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25797303%20AND%20SRC:MED&resulttype=core&format=json

release_76z3ivzzxbfarm2hrjedcqu2ry

7 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/76z3ivzzxbfarm2hrjedcqu2ry

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference